PCH Neurofibromatosis Clinical Updates Provider Educational Conference 2024

Friday, November 1, 2024, 7:55 AM - 5:00 PM, Phoenix Children’s Conference Center, 2632 North 20th Street Phoenix, AZ 85006, Phoenix, AZ


AMA PRA Category 1 Credits™ (6.75 hours), Non-Physician Attendance (6.75 hours)

The 2024 Neurofibromatosis Clinical Updates conference will provide current state of the art and evidence-based insights into the diagnosis, evaluation and management of neurofibromatosis type 1. It will provide an overview and practical guidelines for the lifelong need for ongoing monitoring of patients with neurofibromatosis that face age related risk, including cancer predisposition, from their condition. Primary care provider's collaboration with specialists in delivering an all-encompassing, comprehensive continuum of care is essential to the physical and mental well-being of patients with neurofibromatosis type 1.

1. Implement new insights and strategies to diagnose, manage, and treat children and adolescents with neurofibromatosis type 1 using the most relevant, up-to-date clinical information.
2. Assess important clinical signs and symptoms, and the need for intervention and referral to appropriate specialists, as it relates to patient outcomes in this complex disorder.
3. Apply best practices and the latest evidence-based guidelines in optimal care and management of neurofibromatosis type 1 patients in the primary clinical practice.
4. Recognize potential cancer risks, developmental issues, and other systemic complications of neurofibromatosis type 1.
5. Counsel patients and families on short-term and long-term prognoses, risks and potential treatment options for a variety of neurofibromatosis type 1 associated conditions in the pediatric population.
6. Improve patient care outcomes for children with neurofibromatosis type 1 by accounting for potential risks and complications and collaborating with specialists to ensure best outcome.

https://www.eventbrite.com/e/neurofibromatosis-clinical-symposium-registration-912789868067

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Phoenix Children's. The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Refund and Cancellation Policy

A full refund will be issued for requests received up to 7 days prior to the conference. No refund will be provided once the conference begins. The organization holding the activity reserves the right to cancel or postpone this program if necessary; in the event of cancellation, registration fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Accessibility Statement

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME activity coordinator.

Mitigation of Relevant Financial Relationships

University of Arizona College of Medicine - Tucson Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Friday, November 1, 2024